Literature DB >> 9592623

Metabolism of fibric acid derivatives.

J D Spence.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9592623     DOI： 10.2165/00003088-199834050-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  8 in total

Review 1.  Human P450 metabolism of warfarin.

Authors:  L S Kaminsky; Z Y Zhang
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

2.  Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.

Authors:  R S Lees; A M Lees
Journal:  N Engl J Med       Date:  1995-09-07       Impact factor: 91.245

Review 3.  Drug interactions with fibric acids.

Authors:  A Lozada; C A Dujovne
Journal:  Pharmacol Ther       Date:  1994-08       Impact factor: 12.310

Review 4.  Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Authors:  D B Miller; J D Spence
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

5.  Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine.

Authors:  R Goldberg; D Roth
Journal:  Transplantation       Date:  1996-12-15       Impact factor: 4.939

6.  Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.

Authors:  K S Lown; R R Mayo; A B Leichtman; H L Hsiao; D K Turgeon; P Schmiedlin-Ren; M B Brown; W Guo; S J Rossi; L Z Benet; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  1997-09       Impact factor: 6.875

7.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.

Authors:  P J Neuvonen; K M Jalava
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

8.  In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.

Authors:  C Transon; T Leemann; N Vogt; P Dayer
Journal:  Clin Pharmacol Ther       Date:  1995-10       Impact factor: 6.875
  8 in total
  2 in total

1.  Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir.

Authors:  Kristin H Busse; Colleen Hadigan; Cheryl Chairez; Raul M Alfaro; Elizabeth Formentini; Joseph A Kovacs; Scott R Penzak
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

2.  Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARα agonist) in smokers.

Authors:  Marie N S Gendy; Patricia Di Ciano; William J Kowalczyk; Sean P Barrett; Tony P George; Stephen Heishman; Bernard Le Foll
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.